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Abstract Since the 1970s, clinicians have increasingly
become more familiar with hyperprolactinemia (HPRL) as a
common adverse effect of antipsychotic medication, which
remains the cornerstone of pharmacological treatment for
patients with schizophrenia. Although treatment with sec-
ond-generation antipsychotics (SGAs) as a group is, com-
pared with use of the first-generation antipsychotics,
associated with lower prolactin (PRL) plasma levels, the
detailed effects on plasma PRL levels for each of these
compounds in reports often remain incomplete or inaccurate.
Moreover, at this moment, no review has been published
about the effect of the newly approved antipsychotics asen-
apine, iloperidone and lurasidone on PRL levels. The
objective of this review is to describe PRL physiology; PRL
measurement; diagnosis, causes, consequences and mecha-
nisms of HPRL; incidence figures of (new-onset) HPRL with
SGAs and newly approved antipsychotics in adolescent and
adult patients; and revisit lingering questions regarding this
hormone. A literature search, using the MEDLINE database
(1966–December 2013), was conducted to identify relevant
publications to report on the state of the art of HPRL and to
summarize the available evidence with respect to the pro-
pensity of the SGAs and the newly approved antipsychotics
to elevate PRL levels. Our review shows that although HPRL
usually is defined as a sustained level of PRL above the
laboratory upper limit of normal, limit values show some
degree of variability in clinical reports, making the
interpretation and comparison of data across studies difficult.
Moreover, many reports do not provide much or any data
detailing the measurement of PRL. Although the highest
rates of HPRL are consistently reported in association with
amisulpride, risperidone and paliperidone, while aripipraz-
ole and quetiapine have the most favorable profile with
respect to this outcome, all SGAs can induce PRL elevations,
especially at the beginning of treatment, and have the
potential to cause new-onset HPRL. Considering the PRL-
elevating propensity of the newly approved antipsychotics,
evidence seems to indicate these agents have a PRL profile
comparable to that of clozapine (asenapine and iloperidone),
ziprasidone and olanzapine (lurasidone). PRL elevations
with antipsychotic medication generally are dose dependant.
However, antipsychotics having a high potential for PRL
elevation (amisulpride, risperidone and paliperidone) can
have a profound impact on PRL levels even at relatively low
doses, while PRL levels with antipsychotics having a mini-
mal effect on PRL, in most cases, can remain unchanged
(quetiapine) or reduce (aripiprazole) over all dosages.
Although tolerance and decreases in PRL values after long-
term administration of PRL-elevating antipsychotics can
occur, the elevations, in most cases, remain above the upper
limit of normal. PRL profiles of antipsychotics in children
and adolescents seem to be the same as in adults. The hy-
perprolactinemic effects of antipsychotic medication are
mostly correlated with their affinity for dopamine D2
receptors at the level of the anterior pituitary lactotrophs (and
probably other neurotransmitter mechanisms) and their
blood–brain barrier penetrating capability. Even though
antipsychotics are the most common cause of pharmaco-
logically induced HPRL, recent research has shown that
HPRL can be pre-existing in a substantial portion of anti-
psychotic-naı¨ve patients with first-episode psychosis or at-
risk mental state.
J. Peuskens  J. Detraux  M. De Hert (&)
Department of Neurosciences, KU Leuven, University




Italian Medicines Agency (AIFA), Rome, Italy
CNS Drugs (2014) 28:421–453
DOI 10.1007/s40263-014-0157-3
1 Prolactin (PRL)
Prolactin (PRL) (Lat. pro = for; lac, gen. lactis = milk),
also called lactotrophin hormone, is a polypeptide hormone
that is mainly synthesized and secreted in a pulsatile
manner (with around 10 peaks per day in young adults)
from lactotroph cells of the anterior lobe of the pituitary
gland (i.e., the adenohypophysis) [1–6]. These cells com-
prise between 20 and 50 % of the cellular population of the
gland [4, 5], with those in the more inner zones being more
responsive to dopamine, a neurotransmitter playing a piv-
otal role in the regulation of PRL secretion. Lactotroph
cells in the outer zone are more responsive to thyroid-
releasing hormones, one of the other substances playing a
role in PRL secretion [5]. However, although PRL is typ-
ically thought of as a pituitary-derived hormone, PRL
secretion is not restricted to the pituitary gland [7]. Other
organs and tissues in the body also produce PRL, including
the hypothalamus, telencephalon, brain stem, spinal cord,
choroid plexus, mammary gland, some immune cells and
circumventricular organs [8, 9].
Prolactin, discovered more than 80 years ago [8], is
composed of 199 amino acids, having a molecular weight
of about 23 kDa [4–6, 8, 10–12]. It has been found to be
involved in over 300 separate functions, which can be
divided into the following categories: reproduction, water
and electrolyte balance, growth and development, endo-
crinology and metabolism, brain and behavior and immu-
noregulation [12–14]. Its main physiological functions
include the induction and maintenance of milk production,
breast enlargement during pregnancy, inhibition of hypo-
thalamic gonadotrophin-releasing hormone, and mainte-
nance of proper ovarian function and of progesterone-
secreting structures [3, 6, 12, 15–17]. Despite the fact that
almost 300 functions could be identified for this hormone
in various species, the question remains open as to which of
them are really relevant in humans [8, 18].
2 Physiology
A large variety of stimuli, provided by the environment and
the internal milieu (exercise, suckling, stress, sleep, meals,
sexual intercourse, levels of ovarian steroids, etc.), are
involved in the fine balance of stimulation and inhibition of
PRL release. The secretion of PRL is under complex
control of peptide and steroid hormones and neurotrans-
mitters, which act as inhibitory [PRL-inhibiting factors
(PIFs)] or stimulatory [PRL-releasing factors (PRFs)] fac-
tors by a direct effect on the lactotroph cells or by indirect
pathways (modulators or indirect regulators) [17, 19–21].
The periventricular (periventricular nucleus and arcuate
nucleus) and the medial (paraventricular nucleus and
supraoptic nucleus) hypothalamic subdivisions are the
major regions associated with PRL homeostatis [17, 19]. In
the context of this review, two neurotransmitters are
important to discuss: dopamine and serotonin (5-HT).
2.1 Role of Dopamine in PRL Secretion
Dopamine is the most important hypothalamic PIF [4]. It
exerts a tonic inhibition on PRL secretion, mainly via two
pathways: the tuberoinfundibular dopaminergic (TIDA)
system and the tuberohypophysial tract [4, 17, 19–21]. The
TIDA system, consisting of a population of dopaminergic
neurons found in the arcuate nucleus of the hypothalamus,
is the most important in regulating PRL release in humans.
These dopaminergic neurons release dopamine into the
perivascular spaces of the medial eminence. From here,
dopamine is subsequently transported via long portal ves-
sels to the anterior lobe of the pituitary [4, 17, 19–22]. The
other inhibitory dopamine pathway, the tuberohypophysial
tract, also originates in the arcuate nucleus and projects to
the intermediary and posterior pituitary, and dopamine,
released in the blood, reaches the lactotroph cells via the
short portal vessels [4, 19, 21]. Dopamine binds to the
dopamine D2 receptors (D2R) on the membrane of the
lactotroph cells. D2R stimulation inhibits the PRL gene
transcription, synthesis and release of PRL as well as lac-
totroph proliferation [4, 6, 11, 13, 17, 19, 21, 23–25]. The
TIDA network is partially regulated by an autocrine neg-
ative feedback by PRL on its own release. An increase in
circulating PRL levels results in higher activity of TIDA
neurons, whereas a decrease in circulating PRL levels
lowers their activity [4, 17]. As such, PRL regulates its own
release by acting directly on the hypothalamic dopami-
nergic neurons, probably through regulating the activity of
tyrosine hydroxylase, the rate-limiting enzyme in dopa-
mine synthesis [4, 22].
A blockade of D2R counteracts the tonic inhibitory
effect on the PRL secretion [26]. Inhibition of the dopa-
mine transmission, especially through D2R blockade on the
lactotroph cells, results in disinhibition of PRL secretion:
the stronger the dopamine blockade, the higher the PRL
elevation [27]. Antipsychotics have a D2-blocking effect
and can therefore elevate the secretion of PRL [28, 29].
Conversely, dopamine agonists (e.g., bromocriptine) sup-
press PRL secretion [23].
2.2 Role of Serotonin in PRL Secretion
While hyperprolactinemia (HPRL) is well recognized in
relation to antipsychotic medication and its antidopamin-
ergic activity, there is relatively little awareness of the
impact of substances interfering with serotonergic neuro-
transmission on the PRL levels [21].
422 J. Peuskens et al.
Drugs that increase extracellular levels of 5-HT or are
direct agonists of 5-HT receptors elicit PRL secretion, and
blocking 5-HT synthesis or transmission results in blunted
PRL release [30–33].
5-HT has a stimulatory role in PRL secretion through a
complex, multi-level action on both the hypothalamus and
the pituitary [4]. Although some research has demonstrated
a direct prosecretory effect on the anterior pituitary cells
[34], 5-HT is an indirect modulator of PRL secretion, with
the hypothalamus as its predominant site of action, where
several 5-HT receptors types have been found to play a role
in PRL secretion [17, 19, 21, 35, 36].
The serotonergic pathways involved in the regulation of
PRL secretion originate from cells in the dorsal raphe
nucleus and terminate in the paraventricular nucleus of the
hypothalamus, exerting their action via 5-HT1A and
5-HT2A/C receptors (5-HT2A/CR) [21, 35, 37]. The para-
ventricular nucleus contains cells producing oxytocin and
vasoactive intestinal peptide (VIP), both considered to be
PRFs [21]. The 5-HT-mediated PRL increase is probably
mediated via stimulation of PRFs, of which oxytocin and
VIP are the best studied [17, 21]. The oxytocin cells project
to the posterior lobe of the pituitary, and oxytocin reaches
the anterior pituitary via portal vessels as well as through
the systemic circulation, and stimulates the lactotrophs via
their oxytocin receptors, causing PRL release [38, 39]. The
VIP cells project to the anterior pituitary, where VIP binds
to the receptor on the lactotroph cell membrane, stimulating
PRL release [40]. Moreover, VIP may also be produced in
the pituitary itself, stimulating PRL release by autocrine and
paracrine mechanisms [17]. Furthermore, animal studies
suggest a link between oxytocin and VIP action on PRL
release [41]. Although pharmacological and anatomic data
indicate that the paraventricular nucleus represents a major
regulating site of 5-HT-induced PRL release, ablation of the
paraventricular nucleus does not entirely abolish the PRL
response to 5-HT agonists, demonstrating that other path-
ways also contribute to 5-HT-induced PRL release [42, 43].
An alternate path for 5-HT-induced PRL release is inhibi-
tion of the TIDA dopamine cells. However, there is little
synaptic contact between 5-HT fibers and TIDA cells,
indicating that if direct inhibition of dopamine cells occurs
by 5-HT, it is through volume transmission of 5-HT in this
region [44]. There is more direct evidence for 5-HT stim-
ulation of GABA-ergic neurons in the vicinity of TIDA
cells. Stimulation of these GABA-ergic interneurons will
result in an inhibition of TIDA neurons, releasing the tonic
inhibition of PRL secretion [17, 21, 45].
2.3 Role of Other Substances in PRL Secretion
As already indicated above, PRL secretion is under the
complex control of peptide and steroid hormones and
neurotransmitters, which can act as inhibitory or stimula-
tory factors. Somatostatin, acetylcholine, endothelins,
norepinephrine, growth hormone, etc. are identified as
PIFs. Thyrotropin-releasing hormone (TRH) as well as
angiotensin II, vasopressin, galanin, etc. stimulate PRL
secretion [17, 19, 21, 46]. Estrogen is a physiological
regulator of PRL synthesis in pituitary lactotroph cells [47,
48]. Estrogens can increase PRL secretion in different
ways: through an augmentation of the number of PRL-
secreting lactotroph cells in the pituitary gland; through an
elevation of the sensitivity to TRH; through a decrease in
the number of pituitary dopamine receptors; and through an
upregulation of the expression of the PRL receptor gene [6,
30]. Veselinovic´ et al. [49] showed that estrogen treatment
in healthy volunteers sensitizes women for PRL-elevating
properties of antipsychotic medication. It is also known
that ghrelin, a peptide hormone involved in metabolic
homeostasis, stimulates PRL secretion, most probably by a
direct action on the pituitary somatomammotroph cells
(progenitor cells of lactotroph cells that can produce both
PRL and growth hormone) [50–52]. A relatively large body
of evidence has shown that tachykinins can modify the
secretion of PRL in a rather complex fashion, having a
stimulatory effect at the pituitary level, but in some cir-
cumstances (via modulating hypothalamic dopamine
release) also an inhibitory one [4]. Finally, there is some
evidence to suggest that endogenous opioids play an
important role in regulating PRL secretion, especially in
relation to stressful stimuli. Most stressful stimuli lead to a
reduction in the activity of TIDA neurons through activa-
tion of inhibitory neuronal pathways, with a consequent
increase in PRL secretion [4].
3 Diagnosis of Hyperprolactinemia (HPRL)
3.1 Normal and Elevated PRL Values
Normal serum concentration of PRL varies with sex [11,
16, 53]. Hence, normal PRL levels for men and women are
different, with ranges of 10–20 and 10–25 ng/ml, respec-
tively [54, 55]. There are also marked interindividual dif-
ferences; normal PRL serum levels differ appreciably from
one individual to another [17, 46, 56, 57]. Serum PRL also
displays pronounced circadian variations (up to four times),
with maximal concentrations occurring during sleep [5, 11,
12, 15, 16, 53, 56], with a peak of up to 30 ng/ml [5, 6]
between 4 a.m. and 6 a.m. [6, 55], reaching a nadir during
waking hours [5]. During sleep, PRL secretion is highest
during REM sleep. PRL levels are also subject to seasonal
changes (higher in the spring and summer) [5, 58, 59]. An
increased release of PRL occurs during pregnancy (up to a
maximum of 200 ng/ml) and breastfeeding (up to a
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maximum of 300 ng/ml) [6, 15, 16, 23, 46]. Although PRL
is not commonly recognized as a hormone which changes
significantly within the menstrual cycle or after meno-
pause, it has been found that PRL levels vary significantly
throughout the menstrual cycle [60]. These levels are
higher during the menstrual mid-cycle (particularly the
second half of the cycle) [61], compared with follicular and
luteal phases. It also varies significantly between pre- and
postmenopausal women (higher in premenopausal women)
[60]. Therefore, the utility and accuracy of PRL testing
may be improved by applying specific reference intervals
for each phase of the menstrual cycle, with the recom-
mendation that PRL levels should only be measured in the
follicular phase, well before the mid-cycle [60]. Whether
there is a change in PRL with the onset of menopause
remains controversial. In healthy normoprolactinemic
subjects, both increases and decreases in PRL have been
reported [62]. Finally, serum PRL rises after exercise,
meals, sexual intercourse, minor surgical procedures,
general anesthesia, acute myocardial infarction, an epi-
leptic seizure (including after electroconvulsive therapy)
and other forms of acute stress [5, 6, 55, 61]. Interestingly,
several recent studies reported that current and ex-cigarette
smokers on antipsychotic medication have significantly
lower mean PRL levels, compared with nonsmokers [63–
65]. It is known that cigarette smoking is a potent inducer
of the hepatic cytochrome P450 1A2 enzyme, and smoking
may therefore result in a reduction of serum concentration
of some antipsychotic drugs, which may, in turn, result in
lower PRL levels [63]. However, further studies are needed
to elucidate the underlying mechanism(s) [63, 64].
Hyperprolactinemia is usually simply defined as a sus-
tained level of PRL above the laboratory upper level of
normal [5, 66, 67]. However, pathological HPRL has to be
defined as sustained circulating PRL levels above normal
range in conditions other than, for example, pregnancy and
lactation, when physiological HPRL occurs [8]. Although
the clinician/researcher needs to be aware that laboratory
ranges may differ between sites [67], in most laboratories
and according to the most recent and more conservative
reports, the upper limits for PRL serum concentrations are
set at 20 ng/ml for men and 24–25 ng/ml for non-pregnant,
non-nursing women [68]. Therefore, HPRL is usually
defined as fasting levels at least 2 h after waking above
20 ng/ml in men, and above 25 ng/ml in women [20].
However, these limit values show some degree of vari-
ability in clinical trial reports (or, in many reports, are
simply are not stated), making the interpretation and
comparison of data across studies difficult. Reviewing
numerous studies, we see that limit values are set between
11 ng/ml (for men) and 50 ng/ml (for women) (see
Table 1). Some laboratories also give different ranges for
pre- or postmenopausal women.
Prolactin-secreting pituitary adenomas (prolactinomas)
(about 40 % of pituitary tumors produce PRL) [6] are the
most common cause of PRL levels greater than 100 ng/ml.
Thus, pituitary tumors are an important consideration for
antipsychotic-treated patients with levels above 95–118 ng/
ml [67, 115]. PRL levels above 200 ng/ml almost always
indicate the presence of a lactotroph adenoma [55]. PRL
concentration also correlates with tumor size [5, 116]. A
serum PRL level [200–250 ng/ml is usually due to a
macroadenoma ([1 cm in diameter), rather than a micro-
adenoma (\1 cm diameter) [116, 117]. In the event of a
macroprolactinoma, the PRL concentration can even rise to
values as high as 35,000 ng/ml (see Table 2). However, it
is important to note that PRL is not a perfect tumor marker.
There have been reports of tumor growth of lactotroph cells
in the absence of increasing PRL levels [116–118].
Therefore, the monitoring of PRL levels alone is not ade-
quate to exclude an expanding tumor mass [116]. More-
over, PRL-producing tumors exist ‘‘silently’’ (a clinically
insignificant adenoma) in up to 5–10 % of the adult pop-
ulation [119]. Elevated PRL levels, but \100 ng/ml, are
most commonly due to a medication effect [55], although
increases beyond 300 ng/ml with an antipsychotic medi-
cation have been reported [67, 115].
Although some case reports have noted the resolution of
prolactinoma after switching from a ‘‘PRL-raising’’ to a
‘‘PRL-sparing’’ antipsychotic [120, 121], and some studies
suggest that certain ‘‘PRL-raising’’ antipsychotics may
have a causal relationship with pituitary adenoma [122],
this issue remains controversial [123]. No literature exists
that establishes a causal relationship between antipsychot-
ics and pituitary tumors, or demonstrates that HPRL can
cause a pituitary adenoma, including in normal physio-
logical states of HPRL, such as pregnancy [124]. More-
over, investigation and reporting biases may have
influenced the disproportional reporting of pituitary tumor
in patients on ‘‘PRL-raising’’ antipsychotics [125]. As there
are no prospective studies or randomized trials available,
this area needs further research.
Values that fall within the interval of high PRL levels can
bring about clinically significant symptoms [23]. Serri et al.
[126] provide some rules of thumb regarding PRL levels and
clinical presentations in premenopausal women: marked
PRL excess ([100 ng/ml) is commonly associated with
hypogonadism, galactorrhea and amenorrhea; moderate
PRL excess (51–75 ng/ml) is associated with oligomenor-
rhea; mild PRL excess (31–50 ng/ml) is associated with
short luteal phase, decreased libido and infertility. These
breakpoints help to place some of the more commonly
observed elevations in plasma PRL in clinical perspective
[55]. However, increased PRL levels can occur without
clinical symptoms [127]. Although it has been suggested that
increased PRL levels are believed to be responsible for
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sexual impairment, one is struck by the fact that the evidence
is contradictory and inconclusive [128, 129]. Some studies
have shown an association between sexual side effects and
PRL elevation, while others have failed to support this [129].
It is therefore important to distinguish between symptomatic
and asymptomatic HPRL, although this distinction is seldom
made in the scientific literature [55].
3.2 Measurement of PRL Levels
Despite the well-recognized variability in PRL levels, most
reports do not provide much or any data detailing the
measurement of PRL levels (e.g., the time of sampling).
These may be relevant factors in individual patients who
Table 1 Hyperprolactinemia values according to different studies in
patients receiving antipsychotic treatment [14, 20, 69–114]
Study Hyperprolactinemia values
Tsuboi et al. [69] [18.77 ng/ml (men)
[24.20 ng/ml (women)
Geller et al. [70] [27 ng/ml
Citrome et al. [71] [17.7 ng/ml (men)
[29.2 ng/ml (women)
Kikuchi et al. [72] [20 ng/ml (men)
[25 ng/ml (women)
Nagai et al. [73] [12.8 ng/ml (men ? postmenopausal
women)
[30.5 ng/ml (fertile women)
Pe´rez-Iglesias et al. [74] [17.7 ng/ml (men)
[29.2 ng/ml (women)
Sugawara et al. [75] [13.69 ng/ml (men)
[29.32 ng/ml (premenopausal women)
[15.39 ng/ml (postmenopausal women)
Grootens et al. [76] [18 ng/ml (men)
[25 ng/ml (women)
Li et al. [77] [25 ng/ml (men)
[35 ng/ml (women)
Gopal et al. [78] [18 ng/ml (men)
[30 ng/ml (women)
Aston et al. [79] [15.2 ng/ml (men)
[23.3 ng/ml (women)
Arakawa et al. [80] [12.8 ng/ml (men)
Bushe et al. [81] [18.77 ng/ml (men)
[24.2 ng/ml (women)
Citrome et al. [82] [18.8 ng/ml (men)
[24.2 ng/ml (women)





Kim et al. [85] [20 ng/ml
Byerly et al. [86] [18 ng/ml (men)
[29 ng/ml (non-lactating women)
Konarzewska et al. [87] [17.7 ng/ml
Liu-Seifert et al. [88] [18.77 ng/ml (men)
[24.2 ng/ml (women)
Van Bruggen et al. [89] C15 ng/ml (men)
C22 ng/ml (women)
Tschoner et al. [90] [20 ng/ml (men)
[25 ng/ml (women)
Meltzer et al. [91] [18.77 ng/ml (men)
[24.20 ng/ml (women)
Emsley et al. [92] [18.77 ng/ml (men)
[24.20 ng/ml (women)
Kahn et al. [93] [18 ng/ml (men)
[25 ng/ml (women)
Lu et al. [94] [25 ng/ml (women)
Table 1 continued
Study Hyperprolactinemia values
Hanssens et al. [95] [18.8 ng/ml (men)
[24.2 ng/ml (women)
Yuan et al. [96] [20 ng/ml (men)
[25 ng/ml (women)
Kishimoto et al. [97] [12.78 ng/ml
Howes et al. [98] [14.4 ng/ml
Kinon et al. [99] [18.8 ng/ml (men)
[24.2 ng/ml (women)
Goffin et al. [14] [25 ng/ml
Kelly and Conley [100] C18 ng/ml (men and women)
Schooler et al. [101] [18 ng/ml (men)
[25 ng/ml (women)
Volavka et al. [102] [20 ng/ml (men)






Montgomery et al. [105] [18.4 ng/ml (men)
[26 ng/ml (women)
Cavallaro et al. [106] [18 ng/ml (men)
[29 ng/ml (women)
Halbreich et al. [20] [20 ng/ml (men)
[25 ng/ml (women)
Kinon et al. [107] [18.77 ng/ml (men)
[24,20 ng/ml (women)
Potkin et al. [108] [23 ng/ml
Canuso et al. [109] [23.2 ng/ml (premenopausal women)
Aizenberg et al. [110] [16 ng/ml
Huber et al. [111] [25 ng/ml
David et al. [112] [15 ng/ml (men)
[20 ng/ml (women)
Peuskens and Link [113] C15 ng/ml
Crawford et al. [114] [13.8 ng/ml (men)
[18.4 ng/ml (women)
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have borderline raised levels. A complicating factor during
measurement of PRL levels is the presence of macroprol-
actin2, which is essentially biologically inactive, but may
lead to falsely high PRL levels as measured by many
assays [66]. Conservative estimates suggest that the pre-
sence of macroprolactin leads to misdiagnosis in as many
as 10 % of all reported instances of biochemical HPRL
[90]. Macroprolactinemia can, however, be revealed by
polyethylene glycol precipitation of serum samples [17,
90]. Thus, awareness and understanding of the potential
impact of factors that affect PRL are important in the
interpretation of PRL testing results [16]. When assessing
PRL levels other points to be aware of are [130]:
• All serum measurements must been done by the same
laboratory.
• All bloods must have been drawn in the morning with
the patient in a fasting state.
• To confirm diagnosis, at least one repeated measure-
ment is required after the initial elevated level.
There is a variety of reported units of measurement of
PRL levels. Serum PRL concentrations are usually
expressed in units of either ng/ml (or the equivalent lg/l),
nmol/l, pmol/l, or mIU/l [5, 6]. US data are often presented
in ng/ml, whereas most UK and EU data are in mIU/l [5].
Most clinical papers do not state the conversion factor
needed, while there exists variability in conversion factors
that are reported. In general terms, ng/ml 9 21.2 converts
to mIU/l (although some conversion factors given are as
high as 36) [5, 66, 67, 115], ng/ml 9 43.478 converts to
pmol/l [70], and ng/ml 9 0.043 converts to nmol/l [6].
The reporting of PRL levels remains poor in many
published studies. A baseline plasma PRL level and at least
one follow-up measurement should be reported. However,
several follow-up measurements over a longer (C1 year)
study period are preferable as continuity and longer-term
data are needed. Moreover, there has been a tendency to
report mainly mean PRL values or mean change PRL data
that do not easy allow interpretation of the precise number
of patients developing HPRL or the clinical significance of
these elevations. Not to report categorical data (thus not
telling explicitly how many patients have HPRL) makes it
difficult for clinicians to advise their patients on the
appropriate risk with a particular antipsychotic compound
[131]. Therefore, categorical outcomes for abnormal PRL
levels need to be reported, as well as outcomes on the
severity of the HPRL in individual patients. PRL levels
should also be measured by a morning, fasting, pre-medi-
cation sample. Lastly, it is also important to mention
whether patients at baseline were switched from another
antipsychotic or not, as well as to provide the thresholds
used for the registered (ab)normal plasma PRL values.
3.3 Incidence of HPRL
Hyperprolactinemia is one of the most common endocri-
nological disorders of the hypothalamic-pituitary axis [17].
The estimated incidence of HPRL (serum PRL values
[25 ng/ml) in the non-selected healthy population is low
(0.4 %) [13]. However, this estimate may be too low, given
that autopsy reports state that more than 10 % of the
population have a pituitary tumor [14].
Considering PRL responses to antipsychotic medication,
it is repeatedly found that PRL responses to these medica-
tions are greater in females than in males [49, 107, 132–141].
This difference can be explained by the ability of estrogens to
elevate serum PRL levels and enhance responsiveness to
PRL-releasing stimuli [49, 142]; estrogens increase the
number of lactotrophic cells of the anterior pituitary and act
on the hypothalamus to decrease dopamine content [49].
Among male patients, age was found to have no influence on
PRL concentrations, whereas in women, a younger age was
associated with higher PRL levels, as expected for their
reproductive status [105, 143]; women of reproductive age
experience raised PRL secondary to antipsychotic medica-
tion more frequently than postmenopausal women [107].
Although HPRL is most established in adult patients, it can
be of clinical significance in children and adolescents as well
[144–154]. Once again, post-pubertal girls may be more
sensitive to this adverse effect, given that estrogen stimulates
PRL synthesis and enhances PRL responses to antipsychotic
medication [155].
4 Causes of Elevated PRL Values and HPRL
Considering the complexity of PRL regulation, many fac-
tors can cause HPRL [12, 156]. Table 3 presents the
Table 2 Normal and high prolactin values
Prolactin plasma concentrations
Normal 20 (men) and 25 (women) ng/ml
High From 30–60 to 150–200 ng/ml
Prolactinoma
Microprolactinomas
(B1 cm in diameter)
50–300 ng/ml
(can be as low as 30 ng/ml)
Macroprolactinomas
(C1 cm in diameter)
200–5,000 ng/ml
(can be as high as 35,000 ng/ml)
2 Besides monomeric PRL, which accounts for approximately 85 %
of total PRL in normal sera, higher-molecular-weight variants of PRL
are known. Macroprolactin, which in the majority of cases consists of
antigen-antibody complexes of monomeric PRL and immunoglobulin
G, contributes \1 % to circulating PRL levels. However, in some
patients with supraphysiological PRL levels, macroprolactin was
demonstrated to be the predominant form without eliciting the
classical signs and symptoms of HPRL [90].
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conditions in which elevated PRL values and/or HPRL can
arise [5, 15, 17, 23, 29, 57, 115, 157–159].
5 Methods
To get a fuller picture of the relationship between anti-
psychotics and PRL elevation and because, at this moment,
no review has been published about the effect of the newly
approved antipsychotics asenapine, iloperidone and lur-
asidone on PRL levels, a literature search (1966 until
December 2013), using the MEDLINE database, was
conducted for English-language published reviews, meta-
analyses and clinical trials of first-generation antipsychot-
ics (FGAs), second-generation antipsychotics (SGAs) and
newly approved antipsychotics. The following keywords
were used: ‘‘antipsychotics,’’ ‘‘neuroleptics,’’ ‘‘clozapine,’’
‘‘olanzapine,’’ ‘‘quetiapine,’’ ‘‘amisulpride,’’ ‘‘ziprasi-
done,’’ ‘‘aripiprazole,’’ ‘‘risperidone,’’ ‘‘sertindole,’’ ‘‘pali-
peridone (extended-release and palmitate),’’ ‘‘asenapine,’’
‘‘iloperidone,’’ ‘‘lurasidone,’’ ‘‘schizophrenia,’’ ‘‘prolactin’’
and ‘‘hyperprolactinemia’’. The review is based upon
studies carried out with adults as well as children and
adolescents. We attempted to identify additional studies
through searches of the reference lists of identified studies
and reviews.
6 PRL and Antipsychotics
6.1 General Remarks
After the introduction of chlorpromazine into clinical
practice more than half a century ago, antipsychotic med-
ication rapidly became the cornerstone of pharmacological
treatment for schizophrenia. Antipsychotic drugs are arbi-
trarily divided into first-generation and second-generation
agents (including the newly approved antipsychotics).
Although most antipsychotic drugs are now used to treat a
broad range of symptoms and disorders, their primary
indication remains psychotic disorder, more specifically
schizophrenia and schizophrenia-related disorders.
It was accepted for a long time that serum PRL con-
centrations are not elevated in untreated schizophrenic
patients, unless they have other underlying pathologies
(e.g., prolactinoma) [12, 13, 160]. Several studies [138,
161–165] showed that PRL values in untreated schizo-
phrenic patients were comparable to those of healthy
control subjects. This finding would indicate that the high
PRL values observed in schizophrenic patients treated with
antipsychotic medication have to be attributed to the effects
of this medication rather than to possible underlying effects
of the disease itself [56]. The possibility that schizophrenia
itself causes elevated PRL values seemed therefore exclu-
ded [14]. However, recent research showed that HPRL can
be pre-existing in some patients with schizophrenia [166].
One of these studies on PRL levels in antipsychotic-free
patients with schizophrenia found HPRL ([15.2 ng/ml in
men and [23.3 ng/ml in women) in 23.8 % of antipsy-
chotic-naı¨ve patients with an at-risk mental state for psy-
chosis and in 33.3 % of antipsychotic-naı¨ve patients with
first-episode psychosis [79]. This finding is in accordance
with the results of the European First Episode Schizo-
phrenia Trial (EUFEST) study, showing HPRL ([18 ng/ml
in men and [25 ng/ml in women) in 71 % of first-episode
patients of whom approximately half had never been
exposed to antipsychotic treatment [93], as well as with
other studies of drug-naı¨ve patients [167–169]. The
increased PRL concentrations in antipsychotic-naı¨ve
patients do not appear to be due to important confounding
variables such as gender, smoking and body mass index
(BMI), nor to the effects of elevated thyroid stimulating
hormone (TSH), ghrelin, or cortisol [168]. Therefore, these
findings suggest that HPRL in schizophrenia is not neces-
sarily only caused by antipsychotic medication, but might
already be present in antipsychotic-naı¨ve first-episode
patients and even in prodromal stages [79]. HPRL in these
patients can be caused by general stress associated with the
illness experience [79], or by a pre-existing vulnerability
[168], including a genetic predisposition [170]. One
genetic study suggested a possible abnormality of the
functional -1149 G/T polymorphism of the PRL gene in
schizophrenia, especially in male patients. Based on the
results of this study, it may be speculated that individuals
with a preponderance of the G allele of the polymorphism
react more strongly to stress with a higher production of
PRL [170].
The association between antipsychotic medication and
HPRL has been under investigation since at least the 1970s
[125]. Although HPRL can be found in association with all
antipsychotic medications, these medications differ in their
propensity to cause PRL elevation [171]. The highest rates
of HPRL are reported in association with risperidone,
amisulpride and sulpiride, often in as high as 80–90 % of
all female subjects and consistently greater than with the
FGAs and other SGAs (see 6.3.1.1 and 6.3.1.7). However,
significant rates of HPRL of lesser severity and more
transience have also been reported in association with
several other antipsychotics [66]. On the basis of the sci-
entific literature, a distinction has been made by numerous
authors between antipsychotics with a ‘‘PRL-raising
potential’’ (among which are counted the FGAs and the
SGAs amisulpride, risperidone and paliperidone) and the
‘‘PRL-sparing’’ antipsychotics (clozapine, quetiapine,
olanzapine, ziprasidone and aripiprazole) [46, 57, 105, 109,
140, 172–177]. Nevertheless, this terminology may
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incorrectly lead clinicians to conclude that antipsychotic
medication such as clozapine, quetiapine and even aripip-
razole can never be associated with significant HPRL.
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Thus, although this terminology can be helpful, it over-
simplifies the picture [115]. When looking at individual
studies, in order to make an adequate evaluation of the
PRL-elevating propensity of antipsychotics, information on
PRL baseline values and previous treatment is necessary.
A complex question relating to PRL levels concerns the
persistence of HPRL [66]. With the exception of some
studies (e.g., the study of Eberhard et al. [178] on risperi-
done; see 6.3.1.7), most of the reported PRL data are of too
short duration to make definitive statements regarding this
issue [179].
6.2 PRL and First-Generation Antipsychotics (FGAs)
Elevated PRL values are regularly observed when FGAs
are used. In most patients, such values are an unavoidable
side effect [12, 23]. FGAs induce a significant rise in serum
concentrations of PRL, which are around two to three times
higher than the reference values [53, 55, 56]. The PRL
values that are noted with FGAs are in general lower than
100 ng/ml, although in some patients values of up to
365 ng/ml have been observed [29]. In a study by Mont-
gomery et al. [105], HPRL ([18.4 ng/ml for men,[26 ng/
ml for women, with a mean PRL level of 42.1 ng/ml) was
found in 71 % of the patients treated with FGAs. In 37 %
of the patients, PRL values exceeded twice the normal PRL
values.
It has been suggested that patients receiving long-term
neuroleptic treatment may develop tolerance to the sec-
ondary raising effect, with serum PRL concentration
returning to normal with continued treatment. However,
conflicting results have been reported. A few studies
reported that tolerance can develop with time. Marken
et al. [180], for example, found that 37.5 % of men and
27 % of women, who had been treated with FGAs for at
least 5 years, had normal PRL levels. Brown and Laughren
[181] found that after 4 months of treatment, PRL reached
a stable level, substantially lower than that at the onset of
FGAs treatment and not differing from that after years of
treatment. Other studies, however, reported that tolerance
does not occur. Meltzer and Fang [182, 183] studied serum
PRL levels, before and during long-term administration of
phenothiazines on a twice daily schedule, in 27 newly
admitted schizophrenic patients. By 72 h after the initiation
of treatment, all 27 patients had persistently elevated serum
PRL levels, averaging a 3.2- and 3.8-fold increase in nor-
mal PRL values in men and women, respectively. Serum
PRL levels remained elevated during the 1- to 3-month
period subjects were studied, suggesting there was no tol-
erance to this effect of phenothiazines. A Japanese study
failed to demonstrate tolerance in 27 chronic inpatients
with schizophrenia receiving long-term haloperidol [184].
According to an overview of Meltzer [185] concerning
long-term effects of FGAs on the neuroendocrine system,
serum PRL levels remain elevated in most, but not all,
schizophrenic patients receiving FGAs chronically, if the
dose administered is high enough. Tolerance to these PRL
elevations may develop in some subjects, but even their
PRL levels, though still within normal limits, are higher
than baseline levels.
6.3 PRL and Second-Generation Antipsychotics
(SGAs)
6.3.1 PRL and SGAs in Adults
It has been established that, as a group, the SGAs cause a
lesser elevation of the PRL plasma levels than the FGAs
[90, 138, 186, 187]. Their greater specificity, resulting in a
lesser blockade of the dopaminergic receptors, but also
their stronger 5-HT2AR blockade, is thought to explain the
more limited elevation of the PRL levels [15, 188] (see also
6.5). The notable exceptions in this regard are amisulpride,
risperidone and paliperidone. However, with the exception
of aripiprazole and clozapine, all SGAs have a standard
warning regarding PRL elevations in their US product
labels.
6.3.1.1 Amisulpride Amisulpride, which is structurally
related to the older high-PRL-elevating benzamide, sul-
piride [11, 189], is associated with high rates of HPRL.
Amisulpride also has a pronounced PRL-elevating effect
which appears to be independent of dosage and duration of
administration [190]. Even at relatively low doses (50 mg/
day) amisulpride seems to induce substantially elevated
PRL values [191–195], and brings about greater increases
in PRL values than olanzapine and risperidone [193, 196,
197]. Kopecek et al. [193] found that subjects who receive
doses as low as 50 mg/day have HPRL in almost all cases.
This HPRL is significantly high (mean 113 ng/ml), and
higher in females (160 ng/ml) than in males (48 ng/ml).
Paparrigopoulos et al. [198] found a 100 % prevalence of
HPRL for patients receiving amisulpride. A 12-month,
open-label clinical trial with flexible doses of amisulpride
(mean dose 501.4 ± 283.5 mg/day at month 12) found
HPRL to be the most common (41.9 %) reported adverse
effect among patients with schizophrenia. At baseline, the
mean serum PRL level of all patients was 42.7 ng/ml,
which increased significantly to 92.7 ng/ml at 8 weeks
(p \ 0.001) and then decreased to 73.3 ng/ml at month 12
[199]. Another 12-month trial found HPRL in 75.9 % of
men and 85.7 % of women [200]. Frighi et al. [201],
investigating the safety of antipsychotic medication in
individuals with intellectual disability, found all partici-
pants on amisulpride/sulpiride had HPRL. Therefore,
amisulpride is regarded to be the antipsychotic with the
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potential for maximum PRL elevation [66]. Nevertheless,
HPRL rapidly reverses following amisulpride discontinu-
ation [190, 195].
6.3.1.2 Aripiprazole Aripiprazole belongs to the group of
‘‘PRL-sparing’’ antipsychotics [202–204]. In most studies
with aripiprazole, PRL levels were found to decrease, even
below those expected from placebo, or to remain unchan-
ged over all dosages [83, 85, 86, 94, 108, 123, 200, 206–
221]. However, new-onset HPRL with aripiprazole has
been found [95, 108, 217]. In the study of McQuade et al.
[217], among patients who had normal PRL levels at
baseline, 8 % in the aripiprazole (15–30 mg/day) group
experienced increases above the upper limit of normal (not
defined) at some point during the trial. In general, HPRL
prevalence rates of 3.1–9 % seem consistent [108, 191,
214, 217, 220–222], but can be sometimes higher. For
example, Kwon et al. [83] found 10.7 % of patients to have
an abnormal PRL level ([23 ng/ml) throughout the entire
aripiprazole (10–30 mg/day) study (26 weeks). In another
26-week trial of aripiprazole (mean daily dose at endpoint
18.7 mg) versus ‘‘standard of care’’ agents (olanzapine,
quetiapine or risperidone; mean daily dose at endpoint
12.5 mg, 386.8, and 4.6 mg, respectively), Kerwin et al.
[223] found 16.8 % of aripiprazole-treated patients had
potentially clinically relevant PRL elevations (compared
with 54.4 % in the ‘‘standard of care’’ group). However,
what is meant with ‘‘potentially clinically relevant PRL
elevations’’ is not stated by the authors. Byerly et al. [224]
showed that aripiprazole in combination with risperidone
or olanzapine significantly reduced the PRL levels induced
by these antipsychotics during the first week of treatment.
In combination with risperidone, aripiprazole even
decreased PRL levels to within the normal range of PRL
values. These results are confirmed by other reports [86,
94, 216, 225–230]. The addition of aripiprazole 5 mg daily
to long-acting risperidone was equally associated with a
significant decrease in PRL levels. In an open, uncontrolled
clinical trial with 13 patients with a severe mental disorder
(schizophrenia and other unspecified psychoses), 12
patients showed a decrease in serum PRL levels
(81 ± 46 lg/l at baseline vs. 42 ± 21 lg/l at month 1,
p \ 0.001, 52 % mean reduction) [231]. In two patients
treated with adjunctive aripiprazole, PRL levels reverted to
normality [231]. A recent meta-analysis of five randomized
controlled trials (n = 639) comparing the safety and effi-
cacy of adjunctive aripiprazole versus placebo for anti-
psychotic-induced HPRL found adjunctive aripiprazole to
be both safe and effective as a reasonable choice treatment
for patients with antipsychotic-induced HPRL. Adjunctive
aripiprazole was associated with a 79.11 % (125/158) PRL
level normalization rate. The appropriate dose of
adjunctive aripiprazole may be 5 mg/day [232]. However,
the add-on effects of aripiprazole in reversing antipsy-
chotic-induced HPRL depend on the pharmacological
properties of the pre-existing antipsychotic; adjunctive
aripiprazole treatment reverses effectively HPRL induced
by risperidone and olanzapine, but seems to be less
effective for that induced by benzamide antipsychotics
(amisulpride and sulpiride) [226, 233].
The absence of elevated PRL levels with aripiprazole
can be accounted for by the partial agonism of aripiprazole
with reference to the D2R [66, 234], most likely because it
maintains a low level of activation of pituitary D2R [235].
As a partial D2R agonist, aripiprazole may be the drug of
choice in patients suffering from both psychosis and pro-
lactinoma [121].
Some data indicate that switching to aripiprazole also
may be useful for resolving antipsychotic-induced HPRL
[86, 94, 216]. Even rapid decreases of PRL levels seem to
be achieved with aripiprazole switching strategies [86]. Lu
et al. [94] assessed the time course of changes in antipsy-
chotic-induced HPRL during the process of antipsychotic
switching to aripiprazole (mean dose 18.5 mg/day).
Twenty-three female schizophrenic subjects with risperi-
done (mean dose 4.8 mg/day)- or sulpiride (mean dose
500 mg/day)-induced symptomatic HPRL were recruited
into the study. Serum PRL levels were measured at base-
line, during the combination treatment period, and 4 weeks
after having completed discontinuation of the pre-existing
antipsychotic treatment. Switching antipsychotic drugs to
aripiprazole was effective in reducing serum PRL levels in
schizophrenic patients who received the PRL-raising anti-
psychotics. Mean serum PRL levels at baseline, during
combination period, and after the switch were 97.0 ng/ml,
27.2 ng/ml (p \ 0.001, vs. baseline) and 12.2 ng/ml
(p \ 0.001, vs. baseline), respectively. In a post hoc sub-
analysis of an 8-week, open-label study in outpatients with
schizophrenia (n = 269), Byerly et al. [86] examined
short-term effects on PRL levels during a switch from
risperidone (n = 105) or olanzapine (n = 164) to aripip-
razole 30 mg/day with three switching strategies (I,
immediate aripiprazole initiation with simultaneous
immediate discontinuation of olanzapine/risperidone; II,
immediate aripiprazole initiation while tapering off olan-
zapine/risperidone over 14 days; III, titrating aripiprazole
upwards while tapering off olanzapine/risperidone over
14 days). Mean baseline PRL levels (ng/ml) were within
normal range for the three olanzapine groups (group I,
11.7; group II, 13.2; group III, 11.2), but above normal for
the risperidone groups (group I 39.7; group II 48.5; group
III 33.5). Following aripiprazole initiation, mean PRL
levels decreased significantly (p \ 0.001) at week 1 and
were maintained to week 8 in all groups irrespective of
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prior treatment. Previously elevated PRL levels in the ris-
peridone groups were reduced to within normal range
within 1 week, irrespective of switching strategy.
6.3.1.3 Clozapine Clozapine induces little or no PRL
elevation [11, 15, 30, 46, 110, 131, 155, 236–240] or is
associated with significant decreases of PRL levels (after
switching from a PRL-elevating FGA) [102, 241]. For
example, Breier et al. [241] found that, after a baseline
fluphenazine treatment period, clozapine (mean dose
403.6 mg/day) significantly decreased PRL levels from
53.3 ng/ml at baseline to 12.2 ng/ml at week 6. Long-term
treatment with clozapine seems not to influence PRL levels
significantly. One study showed that even after a treatment
duration of 36 months with clozapine (median dose
300 mg), PRL levels remain low (mean 9 ng/ml) [242].
Despite all these observations, several studies indicated
that clozapine can cause a brief (a few hours) elevation of
PRL levels immediately after the dose is administered [11,
15, 238, 242], or can even be associated with HPRL [105,
243]. Turrone et al. [242] established that clozapine caused
a doubling of the PRL baseline values in the 1–5-h period
after medication administration. Montgomery et al. [105],
who analyzed the data of three electronic databases
(n = 422), determined that 11 % of the patients treated
with clozapine had HPRL ([18.4 ng/ml for men, [26 ng/
ml for women). However, the authors did not specify the
mean treatment time of clozapine. They only noted that
treatment in these chronically mentally ill patients had
been stable for at least 1 month prior to the PRL assay.
Bushe and Shaw [243] reported a prevalence of HPRL of
5 % with clozapine.
6.3.1.4 Olanzapine Olanzapine, an antipsychotic with an
intermediary D2R binding affinity, induces a moderate
elevation of PRL levels [200, 244]. Categorical data show
prevalence rates between 6 and 60 % [66, 74, 76, 99, 105,
114, 191, 245, 246]. Administration of olanzapine causes a
doubling of PRL baseline values 6 h after it is taken [242].
Although switching from a PRL-raising antipsychotic to
olanzapine can lead to a significant reduction [90, 247–
249], even to the upper limit of normal [99], or a nor-
malization of PRL levels [81, 205] in approximately half
up to all of the patients who had elevated PRL levels at
baseline, PRL levels during treatment with olanzapine
remain raised in another substantial proportion (one-third
to more than a half) of patients [205, 245, 246]. Moreover,
olanzapine treatment can lead to new-onset HPRL in
patients with normal PRL levels at baseline [87, 205].
Although Karagianis and Baksh [250], in a high-dose
study (n = 24) on olanzapine, found no significant corre-
lation between mean PRL values and olanzapine high-dose
treatment groups (20, 25, 30 and 40 mg/day, mean duration
of olanzapine therapy 15.3 months), most studies demon-
strated a dose-dependent effect of oral olanzapine on the
plasma PRL level of patients with schizophrenia, with
higher doses associated with higher PRL levels [82, 102,
114, 251–253]. Significant dose-associated changes have
also been identified with olanzapine long-acting injection
[254].
Genetic polymorphisms may be associated with differ-
ences in PRL secretion mediated by SGAs. Cabaleiro et al.
[255] found that some polymorphisms in D2R and
5-HTR2A are involved in PRL levels after administration
of olanzapine. These results agree with those obtained in an
earlier study revealing that PRL secretion induced by
olanzapine (and risperidone) in healthy volunteers was
modulated by Taq1A polymorphism of D2R. However, this
factor was not linked to PRL secretion in quetiapine-treated
healthy volunteers [256].
6.3.1.5 Paliperidone Paliperidone extended-release
(ER), the oral formulation, and paliperidone palmitate, the
long-acting injectable formulation of paliperidone, fre-
quently elevate PRL levels over both short- and longer-
term treatment periods [257–259]. As paliperidone is the
major active metabolite of risperidone, the mechanism of
PRL elevation for paliperidone is likely similar to that of
risperidone [260–262]. However, two recently published
studies suggest that PRL levels seem to decrease after
switching from risperidone to paliperidone in patients with
a psychotic disorder [263, 264]. An analysis of abnormal
PRL values in ten randomized clinical trials, including
3,173 patients treated with paliperidone palmitate, showed
that, overall, at any time, PRL levels were elevated for
38.8 % of the subjects [265]. In general, plasma PRL levels
are elevated to a greater extent in female than in male
patients [77, 78, 91, 92, 257, 266–281], remain mostly
elevated throughout treatment [257] and increases with
increasing paliperidone ER dosage [257, 267, 269, 272,
276–279, 281, 282]. An analysis from a separate 6-day
phase I study in stable subjects with schizophrenia found
similar PRL pharmacokinetic profiles (maximum plasma
concentration, Cmax and area under the curve, AUC) when
subjects received the highest recommended dose of pali-
peridone ER (12 mg/day) compared with an average dose
of risperidone (4 mg/day) [283].
6.3.1.6 Quetiapine Research has shown that quetiapine,
like clozapine, induces virtually no elevation of PRL in the
blood [11, 15, 27, 46, 56, 104, 200, 245, 284–286].
Moreover, many studies show that PRL levels, after
switching, decrease [113, 287–291], even to normal values
[81, 100, 292–294], during treatment with quetiapine.
However, once again, it would be a mistake to claim that
quetiapine (like clozapine) can not cause an elevation of
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PRL values or induce HPRL. Some data indicate that
quetiapine can bring about a transient rise in PRL levels
[11, 15, 30, 242]. Kapur et al. [295] showed that in some
patients, 2–3 h after a single dose, quetiapine
(400–450 mg) corresponded with a transiently high D2R
occupancy at around 60 % and a transiently elevated PRL
level of 19–28 ng/ml. These PRL values returned to normal
within 24 h. In studies that report categorical rates of
HPRL, low prevalence rates in association with quetiapine
have been reported, ranging from 0 to 29 % [66, 104, 105,
154, 191, 296]. Montgomery et al. [105] established that
22 % of the patients treated with quetiapine presented
HPRL ([18.4 ng/ml for men, [26 ng/ml for women).
6.3.1.7 Risperidone Risperidone has a high potential for
PRL elevation. It causes more marked elevations in PRL
than any other SGA [17, 155, 200, 297, 298]. There is also
evidence to suggest that the effect of risperidone (as well as
paliperidone) on PRL may exceed that of FGAs [115, 123]
(with the exception of sulpiride) [299]. A number of dif-
ferent comparative PRL data sets find consistently that
risperidone elevated PRL more commonly and to the same
or a greater degree than haloperidol [66, 101, 105, 127,
140, 300].
When data are reported in a categorical manner, there is
evidence that almost all subjects (72–100 %) receiving oral
risperidone [66, 74, 87, 101, 108, 243, 301] and many
subjects (53–85 %) receiving risperidone long-acting
intramuscular injection have HPRL [66, 172, 243]. The
largest randomized controlled trial (n = 555) reporting
PRL data found an incidence of 73.8 % ([18 ng/ml in men,
[25 ng/ml in women) in risperidone-treated subjects with
first-episode psychosis [101]. However, there can be great
interindividual differences in the elevation of the serum
PRL levels due to risperidone treatment. For example, in
one study PRL levels associated with risperidone treatment
ranged from 26.9 to 320 ng/ml [142].
At therapeutic concentrations of risperidone, serum PRL
levels reach 30–60 ng/ml [240]. However, risperidone can
impact on PRL levels even at relatively low doses [115, 140,
302, 303]. Kim et al. [303] found a mean serum PRL con-
centration with risperidone treatment (mean daily dosage of
3.5 mg/day) of 132.2 ng/ml, after a mean duration of
7.9 weeks. Kinon et al. [140] found that even at doses of
risperidone 2 mg/day, PRL levels were already above the
upper limit of normal for both females (mean PRL =
76.14 ng/ml) and males (mean PRL = 24.53 ng/ml).
The PRL-elevating effect of risperidone is mostly dose
dependent [102, 105, 127, 140, 240, 304–307], even with
long-acting risperidone [308]. Turrone et al. [242] showed
that risperidone administration results in a dose-related
elevation of PRL levels, even after patients have been
taking these drugs for a prolonged period of time. Patients
receiving risperidone (median dose 3 mg/day, range
1–3 mg/day, baseline plasma PRL level 27 ng/ml, median
duration of risperidone treatment 8 months) showed a near
doubling over baseline of PRL levels after risperidone
administration. Compared with olanzapine and clozapine,
whereby PRL levels returned to baseline values by
12–24 h, risperidone-induced PRL levels stayed abnor-
mally high after 24 h.
Although, compared with those on oral risperidone, PRL
levels in patients treated with long-acting risperidone seem
to be generally lower, even with the long-acting form PRL
levels in these patients stay significantly higher than nor-
mal PRL values [308–314]. In the phase III study by Chue
et al. [309], all patients were first stabilized on oral ris-
peridone, after which they were divided into groups that
received long-acting risperidone (25, 50 or 75 mg/day) or
were further treated with oral risperidone (2, 4 or 6 mg/
day). PRL values for many patients remained elevated in
both groups. However, PRL levels dropped significantly
(p \ 0.001) over the 12-week treatment in the long-acting
group, whereas they remained essentially unchanged in the
oral group. Mean PRL levels after 12 weeks of treatment
were 38 ng/ml for oral risperidone (baseline 38.9 ng/ml)
and 32.6 ng/ml for long-acting risperidone (baseline
37.4 ng/ml). This is confirmed in other studies [308, 315].
These observed differences between oral and long-acting
risperidone are probably due to the reduced peak-through
fluctuations of long-acting risperidone compared with oral
risperidone. Nevertheless, long-term administration of oral
risperidone seems also to bring about marked decreases in
PRL values. Eberhard et al. [178] tracked the course of
PRL values over 5 years in psychotic patients treated with
risperidone (n = 59). At study entry, the median PRL level
of the 218 subjects initially treated with risperidone was
1,522 nmol/l (range 24–5,716 nmol/l) or 66 ng/ml.
Although the administration of risperidone was associated
with higher PRL values than the values observed with other
SGAs during this 5 year period, the investigators noted a
strong linear decrease of these values (p \ 0.001) with
risperidone (year 0: 1,192 nmol/l or 52 ng/ml; year 1:
730 nmol/l or 32 ng/ml; year 2: 533 nmol/l or 23 ng/ml;
year 3: 543 nmol/l or 24 ng/ml; year 4: 396 nmol/l or
17 ng/ml; year 5: 412 nmol/l or 18 ng/ml).
Some studies [316, 317] suggest that not risperidone but
its major metabolite 9-hydroxyrisperidone (or paliperi-
done) is the main contributor to the increased serum PRL
levels observed in many risperidone-treated patients. Given
that risperidone and 9-hydroxyrisperidone have shown
similar receptor binding affinities for the D2R, one would
expect an almost equally strong D2R blocking effect on the
lactotrophs and thus equally elevated PRL levels. How-
ever, higher plasma levels of 9-hydroxyrisperidone in
treated patients, as well as its longer half-life and lower
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plasma protein binding, compared with risperidone, has
been proposed to explain these results.
6.3.1.8 Sertindole After it has been suspended in 1998,
because of its potential risk in causing cardiovascular-
related death, sertindole was relaunched to the European
market in 2006. Sertindole has not cause clinically signif-
icant PRL elevations (i.e., above normal reference ranges)
in short- or long-term clinical studies [299, 318–322]. One
study, carried out in 11 European countries, assessing the
safety and tolerability of sertindole (modal dose 16 mg/
day) in the long-term (18 months) treatment of schizo-
phrenia, found mean serum PRL levels decreased [320].
However, according to a recent meta-analysis, assessing
the comparative efficacy and tolerability of 15 antipsy-
chotic drugs in schizophrenia, sertindole causes statistically
significantly higher PRL increases than placebo, which are
not statistically significantly less than those induced by
haloperidol [299].
6.3.1.9 Ziprasidone Similar to most SGAs, ziprasidone
has a lower propensity for HPRL, compared with FGAs
[323]. Most reports indicate a low incidence of PRL ele-
vation and low to moderate levels of HPRL with ziprasi-
done use [11, 15, 103, 234, 240, 245, 297, 324–326].
Several studies found decreased PRL levels after, respec-
tively, 6 weeks [301], 4–8 weeks [90], 18 weeks [327],
44 weeks [328] and 1 year [329] of treatment with zipr-
asidone. However, ziprasidone can also be associated with
HPRL. In one study, switching from aripiprazole to zipr-
asidone (mean dose at last observation 116.8 mg/day) in
patients with schizophrenia induced a significant increase
in serum PRL levels (from 7.2 ng/ml at baseline to
33.8 ng/ml at week 12). HPRL was observed in 54.5 % of
the subjects receiving ziprasidone monotherapy [330].
Analysis of the Clinical Antipsychotic Trials in Interven-
tion Effectiveness (CATIE) data showed 17.3 % in the
ziprasidone group presented HPRL (men [18.77 ng/ml,
women [24.20 ng/ml) [69]. Wu et al. [331] found the
increase of serum PRL levels in drug-naı¨ve schizophrenia
patients treated with ziprasidone (168 ± 17 mg/day) to be
17 ± 11 and 47 ± 51 lg/l in the ziprasidone male and
female group, respectively. Suzuki et al. [332] performed
positron emission tomography (PET) scans with [11C]-ra-
clopride in 12 patients with schizophrenia being treated
with ziprasidone 60 mg twice daily. PRL levels were
highest at 5-h post-dose: PRL levels were higher than the
reference range (males 3–13 lg/l; females 3–27 lg/l) in
seven patients at 5 h (mean ± standard deviation, SD
23.5 ± 13.6 lg/l). None showed HPRL at 23-h scans.
Treatment with ziprasidone can also result in high HPRL
rates in certain vulnerable patient groups, such as first-
episode patients. Grootens et al. [76], in an 8-week double-
blind randomized trial, found that 40 % of patients with
recent-onset schizophrenia on ziprasidone (mean study
dose 104 mg/day) met criteria for HPRL ([18 ng/ml for
men, [25 ng/ml for women) at endpoint. The add-on of
ziprasidone to clozapine does not result in significant PRL
elevations. Zink et al. [333] found no significant changes in
PRL levels in patients who were, after a partial response to
monotherapy with clozapine, randomized to the treatment
condition in which they received clozapine in combination
with ziprasidone (mean dose 134 mg/day) for 6 weeks.
6.3.2 PRL and SGAs in Children and Adolescents
Antipsychotic-induced adverse events can be especially
prominent in vulnerable populations such as children and
adolescents [46]. With reference to the use of antipsychotic
medication in children (B12 years) and adolescents
(12–18 years), one review showed that, in general, all
antipsychotic medication, except clozapine, ziprasidone
and quetiapine, increase the mean PRL level from baseline
values of 8.0 ng/ml to 25–28 ng/ml after 4–8 weeks of
treatment (reference range 0–15 ng/ml) [334, 335]. Inci-
dence rates of HPRL during treatment with risperidone,
olanzapine and quetiapine in this population were 62, 31
and 12 %, respectively [334]. In the same line, a compre-
hensive review of prospective head-to-head and placebo-
controlled comparisons (34 studies) on the efficacy and
safety of SGAs in children and adolescents (n = 2,719)
with psychotic and bipolar spectrum disorders found that
PRL levels increased the most in subjects on risperidone
(mean change ranging from 8.3 to 49.6 ng/ml), followed by
olanzapine (-1.5 ng/ml to ?13.7 ng/ml). Treatment with
aripiprazole was associated with decreased PRL levels,
while clozapine and quetiapine were found to be mostly
neutral [336]. A recently published systematic review and
meta-analysis of the effects of SGAs in children and ado-
lescents aged B18 years confirmed these results [337].
6.3.2.1 Aripiprazole Treatment with aripiprazole in
children and adolescents (up to age 18 years) seems, as in
adults, to be associated with decreased or unchanged PRL
levels [313–318, 336–343]. Moreover, there is also good
evidence that PRL levels can decrease even to subnormal
PRL serum levels (\3 ng/ml for females and\2 ng/ml for
males) [340].
6.3.2.2 Olanzapine Children and adolescents with
schizophrenia may be more susceptible than adults to PRL
increases induced by olanzapine [84]. A meta-analysis of
double-blind, randomized controlled trials using antipsy-
chotic medications for the treatment of a mental disorder in
a pediatric population (children up to 18 years of age)
found olanzapine-treated subjects to have much higher
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odds of an elevated PRL at any time during treatment,
compared with placebo (odds ratio 30.52, p \ 0.00001)
[338]. Another recently published systematic review and
meta-analysis confirmed these results [337].
6.3.2.3 Quetiapine Incidence data of HPRL in children
and adolescents treated with quetiapine seem not to be
higher than those found for adult patients. A review of 29
studies [334] reported an overall incidence of 12 % during
treatment with quetiapine. In the study by Stevens et al.
[304], 20 % of the young male adolescents, who had been
treated for at least 6 weeks with quetiapine
(317.5 ± 238 mg/day), had PRL values that exceeded the
normal values (0–15 ng/ml). A comprehensive review of
prospective head-to-head and placebo-controlled compari-
sons (34 studies) on the efficacy and safety of SGAs in
children and adolescents (n = 2,719) with psychotic and
bipolar spectrum disorders found treatment with quetiapine
mostly to be neutral [336].
6.3.2.4 Risperidone The most and best data concerning
children and adolescents are available for risperidone
[334]. The meta-analysis of Pringsheim et al. [338] found a
change in PRL level from baseline to endpoint to be higher
in risperidone-treated versus placebo-treated children, with
a mean difference of 44.57 ng/ml (p \ 0.00001). Geller
et al. [70], in the initial management of children (mean age
11 years) with mania, found risperidone to be associated
with HPRL (44.8 ng/ml after 8 weeks of treatment, base-
line 7.2 ng/ml, p \ 0.001), which raises concern for long-
term treatment. Ercan et al. [344] found a significant
increase (p \ 0.05) in PRL levels after 8 weeks of treat-
ment with risperidone (70 ng/ml at week 8, baseline
5.3 ng/ml) in preschool children (mean age 42.4 months)
with conduct disorder and severe behavioral problems. In
another study with adolescents and young adults (mean age
16 years) with anorexia nervosa, PRL levels were signifi-
cantly increased for risperidone-treated subjects at week 7
(54.4 ng/ml, baseline 15.4 ng/ml vs. placebo 8.9 ng/ml,
baseline 13.7 ng/ml, p \ 0.001) [345]. In a report on a
large population of adolescents with schizophrenia
(n = 257, mean patient age 15.6 years), Haas et al. [346]
observed elevations in PRL to levels [100 ng/ml in 18 %
of adolescent schizophrenic patients after 8 weeks of
treatment with 4 mg/day of risperidone. Eight short-term
risperidone studies (n = 739) with an average duration of
4.6 weeks showed an increase of PRL from 7.9 ng/ml at
baseline to 27.6 ng/ml at endpoint. Further treatment
showed a decrease to 17.7 ng/ml after 1 year of treatment
and to 24.9 ng/ml after 2 years of treatment [334]. In
children and adolescents treated with risperidone, this
pattern, consistent with the development of PRL tolerance
over time, has also been shown by other research. Migliardi
et al. [153] found mean PRL levels at 6 and 12 months to
be lower than at the first month (baseline 8.4 ng/ml,
1 month 30 ng/ml, 6 months 27.9 ng/ml, 12 months
23.4 ng/ml). Nevertheless, as with olanzapine, vigilance to
PRL elevation in all children treated with risperidone is
necessary. More rapid CYP2D6 metabolism as well as
polymorphic variation in the D2R may be important
pharmacogenetic factors determining the risk for risperi-
done-induced HPRL in children and adolescents [61].
Lawsuits have been filed against Johnson & Johnson
alleging that risperidone causes male breast tissue
enlargement. The Risperdal FDA warning label states that
clinical trials found gynecomastia in 2.3 % of children and
adolescents treated with risperidone [347]. Trials have
already begun, resulting in some noteworthy settlements
[348]. Currently, several law firms are investigating the
potential for more side-effect lawsuits regarding gyneco-
mastia in young boys treated with risperidone [348, 349].
Although risperidone, according to a recent evidence-based
review, has been identified as one of the medications
probably associated with gynecomastia, the authors of this
review state that most of the reported drug–gynecomastia
associations are based on poor quality evidence [350].
Moreover, gynecomastia has also been mentioned as a
potential side effect in other FDA product labels of SGAs
(e.g., olanzapine, ziprasidone, quetiapine), FGAs, and
selective 5-HT reuptake inhibitors (e.g., sertraline).
6.3.2.5 Ziprasidone Data on the use of ziprasidone in
children are scarce [334, 338]. In general, PRL levels with
ziprasidone appear to be lower than what is typically seen
in children or adolescents taking olanzapine or risperidone
[334, 346]. Moreover, PRL changes with ziprasidone in
younger patients mostly are small and transient [351].
6.3.3 PRL and SGAs in First-Episode Patients
Studies have identified younger, antipsychotic-naı¨ve
patients with first-episode psychosis as a population vul-
nerable to cardiovascular and metabolic adverse effects
with any antipsychotic [352–354]. As already mentioned
above, research has shown that HPRL can occur in about
one-third of antipsychotic-naı¨ve first-episode schizophrenic
patients, and in about one-fifth of antipsychotic-naı¨ve
patients with an at-risk mental state for psychosis [79, 93,
169]. There are indications that this HPRL might be due to
a general stress associated with the illness experience and/
or to a pre-existing vulnerability [168]. These findings have
implications for clinical practice in that PRL should be
measured in first-episode patients before starting treatment
with antipsychotics [79, 169], not only to ensure that HPRL
is not a pre-existing condition, but also, if necessary, to
consider choosing a ‘‘PRL-sparing’’ antipsychotic [79].
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Furthermore, it might be speculated that stress-induced
HPRL plays a role in triggering the outbreak of acute
psychotic symptomatology as PRL, through feedback, can
increase dopamine. This would make this population even
more vulnerable for ‘‘PRL-elevating’’ antipsychotics.
However, the latter is certainly speculative and still needs
further research [169, 355]. Moreover, the high level of
stress, inducing PRL elevations in a substantial proportion
of first-episode patients, can be secondary to the acute
psychotic symptoms at the moment of admission.
Only a few studies are available that describe PRL changes
in first-episode patients treated with SGAs. The results of
these studies suggest that the effects of SGAs on PRL-levels in
this population follow the same pattern as in adult schizo-
phrenic patients. The presented data do not suggest that, at
least for adults, first-episode patients, as a group, are more
sensitive to PRL elevations, compared with adult schizo-
phrenic patients. Nevertheless, careful attention should be
given to drug selection and the lowest possible effective doses
for first-episode patients with HPRL at baseline.
6.3.3.1 Amisulpride According to the results of the EU-
FEST study, more first-episode patients on amisulpride
(89 %) had HPRL ([18 ng/ml in men and [25 ng/ml in
women) than those on the other SGAs [olanzapine (50 %),
quetiapine (41 %) and ziprasidone (46 %)] (p = 0.017).
Moreover, taking amisulpride resulted in greater increases
in PRL values per month (p \ 0.0001) [93].
6.3.3.2 Aripiprazole Aripiprazole seems to be a well-
tolerated antipsychotic agent in patients with first-episode
schizophrenia. However, few studies have been specifically
designed to test the safety of aripiprazole for the treatment
of these patients. Lee et al. [211] investigated the thera-
peutic efficacy and tolerability of aripiprazole for treating
first-episode schizophrenia following 8 weeks of treatment
in routine clinical conditions. PRL levels after 8 weeks of
treatment with aripiprazole were not significantly different
from those at baseline. A 26-week prospective study with
300 schizophrenic patients, of whom 106 patients were
drug-naı¨ve first-episode patients, found that serum PRL
levels significantly decreased from baseline levels (week 8,
-20.55 ng/ml, p \ 0.001; week 26, -14.46 ng/ml,
p \ 0.001). Only 10.7 % of patients had an abnormal PRL
level ([23 ng/ml) throughout the entire study. There was
no significant difference in serum PRL levels between first-
episode patients and recurrence patients [83].
6.3.3.3 Olanzapine Pe´rez-Iglesias et al. [74] investigated
the long-term (up to 1 year) effect of haloperidol, olanza-
pine and risperidone on serum PRL levels in a naturalis-
tically treated first-episode psychosis population
(n = 110). After 1 year, most of the patients in the
olanzapine arm had PRL levels that fell within the refer-
ence range (\29.2 ng/ml for women and \17.7 ng/ml for
men). These findings are in agreement with other studies
that have reported no significant or transient PRL eleva-
tions with olanzapine treatment [356, 357].
6.3.3.4 Quetiapine In a small study with only 14 first-
episode schizophrenic patients, comparing PRL levels at
baseline with those after 12 weeks of treatment with que-
tiapine, Tauscher-Wisniewski et al. [358] found no sig-
nificant difference in the elevation of PRL. All PRL levels
at baseline and after 12 weeks of quetiapine treatment were
in the normal range, with the exception of a slightly ele-
vated level in an antipsychotic-naı¨ve patient at baseline,
which resolved at follow-up.
6.3.3.5 Risperidone A long-term (up to 1 year) study
[74], investigating the effect of haloperidol, olanzapine and
risperidone on serum PRL levels in a naturalistically treated
first-episode psychosis population (n = 110), found that
after 1 year of treatment, elevated PRL levels (C29.2 ng/ml
for women and C17.7 ng/ml for men) persisted in most
patients treated with risperidone. Patients treated with ris-
peridone experienced a substantial increase at 3 months,
resulting in PRL levels above the reference range in 90 % of
men and 87 % of women. The levels decreased at 1 year,
although still more than 70 % of the patients remained
above the normative range. Van Bruggen et al. [89] com-
pared the effect of olanzapine and risperidone on hormonal
state in 40 patients with a first-episode psychosis (HPRL
defined as C15 ng/ml for men and C22 ng/ml for women).
All patients (100 %), both male and female, using risperi-
done had increased PRL levels, whereas only four patients
(17.4 %) (males) using olanzapine had increased PRL lev-
els. Takahashi et al. [357] found that, after an unsuccessful
12-week treatment with olanzapine (mean dose 16.4 mg),
plasma PRL concentration significantly increased after
switching from olanzapine to risperidone in first-episode
patients. Mean PRL concentration of both men and women
significantly increased from 6.5 to 16.9 ng/ml and from
17.4 to 54.2 ng/ml, respectively (p \ 0.001).
6.3.3.6 Ziprasidone In an 8-week, open-label, multicen-
ter trial with 27 first-episode patients [359] treated with
ziprasidone (mean total daily and endpoint doses were
120.30 ± 40.34 and 131.85 ± 51.22 mg/day, respec-
tively), no significant differences in PRL levels from
baseline to last observation were found.
6.4 PRL and Newly Approved Antipsychotics
In 2009 and 2010, three new antipsychotics were approved
by the FDA: asenapine (SaphrisTM, Schering-Plough,
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Kenilworth, NJ, USA), iloperidone (FanaptTM, Vanda
Pharmaceuticals, MD, USA), and lurasidone (LatudaTM,
Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA)
[360]. These newly approved antipsychotics appear to
share the same primary mechanism of action with the
SGAs. Like most other SGAs, each of these newly
approved antipsychotics binds with relatively high potency
to 5-HT2A and D2R: iloperidone and asenapine display
more potent antagonist activity at 5-HT2AR than D2R,
while lurasidone displays relatively equivalent binding at
both sites [361, 362]. All three agents are FDA approved
for the acute treatment of schizophrenia in adults. Asena-
pine is also approved for the maintenance treatment of
schizophrenia and as a monotherapy or as an adjunct to
lithium or valproate for the acute treatment of bipolar
manic or mixed episodes, with or without psychotic fea-
tures [361, 363–370].
6.4.1 Asenapine
Asenapine has a low propensity to cause PRL elevation
[361, 371–375]. The PRL profile of asenapine appears to
be similar to that of clozapine [376]. Thus, PRL elevation
can occur, but at a rate lower than that observed for
olanzapine [299, 377, 378] or risperidone [299, 369].
Incidence rates of clinically significant HPRL are generally
low [379]. In studies with patients with acute schizophre-
nia, HPRL (C2 9 upper limit of normal) occurred in 9 %
of asenapine recipients (asenapine 5 mg/day) [379, 380].
Incidence rates of marked HPRL (C4 9 upper limit of
normal) with asenapine in acute and stable schizophrenia,
and bipolar patients were 4–5 % (asenapine 5 and 10 mg
BID or twice a day) [376], 2.8 % (asenapine mean dose
17.5 mg/day) [381] and 6.5 % (asenapine mean dose
16.3 mg/day) [382], respectively. Studies [382–385]
examining the long-term safety of asenapine in patients
with schizophrenia and bipolar disorder showed small
mean declines in PRL levels. In the 52-week, double-blind
comparison of asenapine (5 or 10 mg BID, n = 913) and
olanzapine (10–20 mg once daily, n = 312) by Schoe-
maker et al. [384], plasma PRL levels decreased within the
first 2 weeks from elevated levels at baseline (between 28
and 30 ng/ml) to normal PRL levels in both treatment
groups and remained relatively stable during the remainder
of the study. During the extension phase [385], there were
only minor further changes in PRL levels.
6.4.2 Iloperidone
As with other drugs that antagonize D2R, iloperidone
elevates PRL levels [386]. However, the effect of iloperi-
done on PRL is reported to be low [360, 361, 387–395] and
transient with acute onset of treatment [362]. Short-term
[389, 396] as well as long-term studies [397] showed PRL
levels generally decrease or remain unchanged during ilo-
peridone treatment. However, there does appear to be a
potential for PRL elevations in some subjects [389, 398,
399]. In a pooled analysis of three 6-week, prospective,
randomized, multicenter, double-blind, placebo- and com-
parator-controlled trials (n = 1,943), patients were
exposed to three dose ranges of iloperidone (4–8, 10–16
and 20–24 mg/day). PRL levels were generally decreased
after treatment with two iloperidone dosages; least squares
mean changes in PRL from baseline to endpoint were -38
and -23.1 ng/ml in patients receiving iloperidone 4–8 and
10–16 mg/day, respectively. PRL levels were not available
for the iloperidone 20–24 mg/day group [396]. However,
some other data suggest that higher doses of iloperidone
can actually induce HPRL. In a 4-week, double-blind,
placebo-controlled trial, 14.8 % of iloperidone (24 mg/
day)-treated patients with acute exacerbations of schizo-
phrenia had values outside the upper extended reference
range for PRL (not defined), compared with 1.5 % of
patients in the placebo group [389]. The insert label of
iloperidone, referring to the same trial, however, mentions
that elevated plasma PRL levels were observed in 26 % of
adults treated with iloperidone 24 mg/day, compared with
12 % in the placebo group [386]. Nevertheless, mean PRL
change from baseline remained almost unchanged
(?2.6 ng/ml) compared with a decrease of 6.3 ng/ml in the
placebo group [389]. Results from a very recent open-label
extension trial showed essentially unchanged or decreased
levels of serum PRL during long-term (25-week) treatment
with iloperidone 24 mg/day (12 mg BID). PRL mean
changes from baseline to endpoint for patients switched
from ziprasidone and placebo to iloperidone were -7.7 ng/
ml (SD 38.7) and ?5.1 ng/ml (SD 14.6), respectively. For
patients who continued iloperidone treatment, mean PRL
change from baseline to endpoint was -15.2 ng/ml (SD
27.9) [397].
6.4.3 Lurasidone
Although lurasidone is reported to induce modest, dose-
dependent PRL elevations [400, 401], especially at the
beginning of treatment [402], as well as HPRL in some
patients [71, 403, 404], in many patients it seems to be
associated with no clinically meaningful PRL alterations
[71, 405–408].
Product labeling notes that short-term, placebo-con-
trolled trials found small dose- and gender-related (higher
in females) effects on PRL levels, with a median change
from baseline to endpoint of 0.4 ng/ml for all lurasidone-
treated schizophrenic patients (-1.1 ng/ml with 20 mg/
day, -1.4 ng/ml with 40 mg/day, -0.2 ng/ml with 80 mg/
day, 3.3 ng/ml with 120 and 160 mg/day), compared with
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-1.9 ng/ml for placebo [404]. The proportion of patients
with PRL elevations C5 9 upper limit of normal (not
defined) was 2.8 % for lurasidone-treated patients versus
1 % for placebo-treated patients. For women, this occurred
in 5.7 % for lurasidone versus 2 % for placebo; for men in
1.6 % for lurasidone versus 0.6 % for placebo [404]. In a
6-week, double-blind, placebo-controlled trial with a fixed
dose of lurasidone 80 mg (n = 90) or placebo (n = 90),
treatment with lurasidone was associated with a small but
significant median increase in PRL levels at endpoint
compared with placebo (?2.4 vs. -0.3 ng/ml, p \ 0.05).
Larger median increases were observed in the small group
of women (?9.2 ng/ml) compared with in men (?1.4 ng/
ml). A moderate correlation was seen between serum lur-
asidone concentrations and PRL levels. Three patients had
treatment-emergent PRL concentrations between 50 and
100 ng/ml at endpoint [409]. Pooled data from five double-
blind, placebo-controlled, short-term studies of schizo-
phrenia patients (n = 1,004) with an acute exacerbation
showed the mean end-point change in PRL (ng/ml) was
?1.1 for lurasidone vs. -0.5 for placebo [410].
Consistent with prior short-term studies of lurasidone,
there was no indication for clinically relevant changes in
PRL in four very recently published short-term studies on
lurasidone [401, 403, 411, 412]. In the randomized,
6-week, open-label study of McEvoy et al. [411] (lurasi-
done 40–120 mg/day), mean changes from baseline to last-
observation-carried-forward (LOCF) endpoint in PRL
concentrations were -0.5 and 2.0 ng/ml for male and
female patients, respectively. PRL C5 9 upper limit of
normal (not defined) was observed in 2/219 subjects
(0.9 %), all in the randomized group that initially received
lurasidone 80 mg/day for 14 days. Mean change from
baseline to LOCF endpoint in PRL concentrations in this
dosage group was also higher (9.6 ng/ml) for female
patients, compared with all other dosages/gender groups
[40 mg/day for 2 weeks and 40 mg/day for 1 week,
increased to 80 mg/day on day 8 for week 2 (up-titration
group)], where mean changes in PRL concentrations
decreased or remained almost unchanged. In the same line,
the 6-week, randomized, placebo-controlled study of Nas-
rallah et al. [403] showed modest increases in PRL fol-
lowing treatment with lurasidone (40, 80 or 120 mg/day),
compared with placebo. Median changes from baseline
PRL levels were -0.9, 1.3 and 2.4 ng/ml for patients
receiving lurasidone 40, 80 and 120 mg/day, respectively,
compared with 0.4 ng/ml for those receiving placebo.
Changes were greater among female than among male
patients, particularly in those receiving lurasidone 120 mg/
day (median change, 1.4 ng/ml for men and 6.4 ng/ml for
women). However, a change from normal to high
([17.7 ng/ml for men, [29.2 ng/ml for women) PRL lev-
els occurred in 8.3, 16.1 and 19.7 % of patients receiving
lurasidone 40, 80 and 120 mg/day, respectively, compared
with 4.9 % of patients receiving placebo. Ogasa et al. [401]
found median PRL levels at the week 6 LOCF endpoint
were modestly increased relative to baseline in the lurasi-
done 40 (3.5 ng/ml) and 120 mg/day (7.7 ng/ml) groups,
but not in the placebo group (-1.3 ng/ml). Again, a sex
difference was observed, with lurasidone producing greater
increases in PRL in women (3.8 and 21.1 ng/ml in the
lurasidone 40 and 120 mg/day, respectively) than in men
(3.4 and 5.6 ng/ml in the lurasidone 40 and 120 mg/day,
respectively). Two patients discontinued the study because
of elevated PRL [200 ng/ml. Finally, Loebel et al. [412],
in another 6-week, randomized, double-blind, placebo- and
active-controlled trial, found dose-related median changes
in PRL levels at the 6-week LOCF endpoint for the lur-
asidone 80 and 160 mg/day treatment groups to be 0.8 and
3 ng/ml, respectively. This increase in PRL levels was
found primarily in female subjects.
Uncontrolled longer-term trials (primarily open-label
extensions) reported decreases in PRL concentrations.
Lurasidone was associated with a median change in PRL of
-0.9 ng/ml at week 24, -5.3 ng/ml at week 36, and
-2.2 ng/ml at week 52 [404]. One uncontrolled open-label
extension study even reported a mean change of -12.7 ng/
ml at week 52 [413]. A very recently published open-label
extension study by Stahl et al. [414] observed small
changes in PRL levels. PRL mean changes from baseline to
endpoint (month 6) for patients switched from olanzapine
and placebo to lurasidone were -5.6 ng/ml (SD 10.8) and
?6.0 ng/ml (SD 18.9), respectively. For patients who
continued lurasidone treatment, mean PRL change from
baseline to endpoint was ?2.7 ng/ml (SD 37.0). Little
change in PRL concentrations from baseline to endpoint
were equally reported in controlled trials. A 12-month,
double-blind, active-controlled study on the long-term
safety and tolerability of lurasidone in schizophrenia
showed essentially no change in PRL levels for male as
well as female patients treated with once-daily, flexible-
dosed lurasidone (40–120 mg). Median changes from
baseline to endpoint (month 12) were -0.5 and ?0.1 ng/ml
for male and female patients, respectively [71].
Recently, a systematic review and exploratory meta-
analysis [415] of randomized, placebo-controlled trials was
conducted by our research group to assess the efficacy of
paliperidone (ER formulation), iloperidone, lurasidone and
asenapine on several dimensions of symptoms (positive,
negative, general psychopathology, depression, anxiety), as
well as their tolerability profile in the short-term treatment
(B12 weeks) of schizophrenia and bipolar disorder, com-
pared with placebo. Although all these antipsychotics sta-
tistically significantly (p \ 0.05) increased PRL levels
more than placebo, paliperidone especially was associated
with a higher risk to produce PRL increase, compared with
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placebo [relative risk 8.52, confidence interval (CI)
4.94–14.67; number needed to harm 2.3, CI 1.3–4.4].
Whereas, compared with placebo, mean changes in PRL
levels (ng/ml) with asenapine [weighted mean difference
(WMD) 4.517, CI 1.882–7.152] and lurasidone (WMD
9.13, CI 4.9–13.3) treatment were low to moderate, pali-
peridone was associated with substantial and consistent
increases in serum PRL, both in men (WMD 23.85, CI
18.56–29.14) and women (WMD 71.23, CI 54.57–87.89).
The mean change in PRL levels (ng/ml) with iloperidone
treatment, compared with placebo, was also high (WMD
26.87, CI 12.27–41.47). However, as only one report
(containing four trials) on iloperidone was included in this
analysis and the heterogeneity value for these results was
extremely high (98.5 %), one should consider this result to
be unreliable. Therefore, we concluded that asenapine,
showing a low propensity to cause PRL elevation at the
beginning of treatment, has a PRL profile that appears to be
similar to that of clozapine; lurasidone is probably more
comparable to ziprasidone and olanzapine; paliperidone
elevates PRL levels in a fashion similar to risperidone.
A recently published meta-analysis of 212 blinded,
randomized controlled trials (n = 43,049), comparing the
efficacy and tolerability of 15 antipsychotic drugs in
schizophrenia, found that aripiprazole, quetiapine, asena-
pine and iloperidone did not cause significantly increased
PRL concentrations, compared with placebo. Paliperidone
and risperidone were associated with significantly greater
PRL increases than all other drugs. Because of methodo-
logical reasons, clozapine and amisulpride could not be
included in the analysis. The ranking in order of PRL
increase presented by these authors is as follows: amisul-
pride [ paliperidone [ risperidone [ lurasidone [ zipr-
asidone [ iloperidone [ olanzapine [ asenapine [
placebo [ quetiapine [ aripiprazole [299].
Based on our review, PRL side-effect profiles of SGAs
and newly approved antipsychotics are given in Table 4.
6.5 Possible Explanations of the PRL-Elevating
Tendency of Antipsychotics
Several hypotheses have been put forward to explain the
different PRL profiles of antipsychotic medication. A cor-
relation has been proposed between the fastness of disso-
ciation from the D2R and the PRL-sparing properties of
certain antipsychotics (‘‘fast dissociation hypothesis’’); an-
tipsychotics associated with lesser degrees of PRL elevation
have fast D2R dissociation [5]. Clozapine and quetiapine
have the fastest rate of dissociation from D2R; olanzapine
has an intermediate rate of dissociation [416]. Quetiapine,
as an example of an antipsychotic with fast dissociation, is
associated with central D2R occupancy that falls from ini-
tial blockade of 60–70 % at 2 h post-dosing to around 30 %
at 24 h [417]. Conversely, FGAs, as a group, and risperi-
done dissociate slowly from the D2R, resulting in more
prolonged blockade and therefore greater PRL release [5,
418]. However, although its high PRL risk is well known,
amisulpride is rapidly dissociated from the D2R [416, 419].
Moreover, according to a recent study, haloperidol, also a
highly PRL-releasing antipsychotic, showed a rather fast
dissociation profile [420]. It is thus conceivable that other
factors, in addition to kinetic properties, contribute to the
PRL-releasing properties of antipsychotics.
The different penetration potencies of the various anti-
psychotics with reference to the blood–brain barrier are
another explanation that has been put forward. While the
antipsychotic effect is based on the antagonism of receptors
situated within the central nervous system, PRL elevation
is associated with blockade of D2R at the level of the
anterior pituitary lactotroph cells [420]. Anatomically, the
pituitary gland lies outside the blood–brain barrier [5, 27].
The lesser ability of amisulpride, sulpiride and risperidone,
in comparison with olanzapine and quetiapine, to penetrate
this barrier could explain the tendency of these compounds
to induce elevated PRL values [80, 316, 418]. Their lesser
penetration at therapeutic dose levels leads to a greater
D2R occupancy in the pituitary area and therefore to a
greater increase of the PRL values [316]. Especially for
amisulpride, a decreased penetration of the blood–brain
barrier would explain the marked tendency of this medicine
to cause a rise in PRL values [195, 421]. This hypothesis is
supported by the observation that domperidone, a D2
blocker that does not cross the blood–brain barrier, is
associated with significant PRL elevation [422].
The quantification of dopamine D2R occupancy in the
pituitary by several antipsychotics using PET scans has not
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been reported until recently. Arakawa et al. [80] demon-
strated that the D2R occupancy in the pituitary was a
predictor of HPRL. These researchers measured dopamine
D2R binding of risperidone, olanzapine, haloperidol and
sulpiride in the pituitary (and temporal) cortex in schizo-
phrenic patients. A significant positive correlation was
observed between the plasma concentration of PRL and
dopamine D2R occupancy in the pituitary (p = 0.001) by
the various antipsychotic drugs. The study also indicated
that a 50 % D2R occupancy in the pituitary might represent
a threshold level of HPRL. The brain/plasma concentration
ratio, indicating the penetrating capability across the
blood–brain barrier, seemed to be a good characteristic
biomarker of each antipsychotic drug for the risk of HPRL
at therapeutic dose.
The largest study to date (n = 481) [69], investigating
the relationship between serum PRL concentration and
estimated D2R blockade with risperidone (n = 172),
olanzapine (n = 211) or ziprasidone (n = 98) in patients
with schizophrenia, demonstrated a threshold of HPRL at
73 % of striatal D2R occupancy. However, this threshold
seems to differ among antipsychotic drugs. The cut-off
points for HPRL were 68–70 % for risperidone, 77 % for
olanzapine and 55 % for ziprasidone. This means the
threshold for HPRL in D2R occupancy may lie somewhat
on the lower side of the established therapeutic window
with antipsychotics (i.e., 65–80 %), and therefore high-
lights the need for the use of the lowest possible dose to
avoid this hormonal side effect.
However, D2R blockade on the lactotrophs certainly is
not the sole major cause leading to HPRL [49, 420]. In the
first systematic examination of the effects of different an-
tidopaminergic mechanisms on PRL concentration in
healthy volunteers, Veselinovic´ et al. [49] performed a
7-day intervention with three substances with entirely dif-
ferent mechanisms of action: aripiprazole (partial D2R
agonist), haloperidol (D2R antagonist) and reserpine (a
vesicular monoamine transporter type 2 blocker). The
completely different antidopaminergic mechanisms of
haloperidol and reserpine both resulted in a significant
increase in PRL levels. PRL levels changed significantly
with haloperidol (from 177.2 ± 74.6 to
350.7 ± 202.6 mU/l, p \ 0.0001) but not after aripipraz-
ole (from 160.9 ± 65.0 to 189.6 ± 209.6 mU/l, p = 0.69)
or placebo (from 211.6 ± 113.4 to 196.1 ± 85.6 mU/l,
p = 0.8). However, reserpine, not directly interacting with
D2R, caused the most distinct increase (from 149.6 ± 80.2
to 540.3 ± 280.8 mU/l, p \ 0.0001). Thus, these findings
indicate that the dopaminergic regulation of PRL secretion
is not only related to the D2-like dopamine receptors on the
lactotroph cells itself. Although PRL release is controlled
primarily by dopamine acting on D2R, other neurotrans-
mitter receptor systems probably are involved. Therefore,
the serotonergic antagonistic activity of the SGAs has also
been proposed as another explanation [423].
Finally, genetic factors also seem to play an important
role. Genetic D2R polymorphisms may explain why some
individuals are more prone to develop HPRL [424, 425].
The TaqIA A1 [26, 424] and the A-241G alleles are
associated with higher PRL concentration, and adverse
events potentially related to HPRL were found to be four
times more common in TaqIA A1 allele carriers [425].
7 Consequences of HPRL
Multiple signs and symptoms are associated with HPRL
(see Table 5) [6, 15, 23, 46, 57, 159, 426, 427].
For years there has been considerable debate about the
impact of HPRL in schizophrenic patients. Frequently,
HPRL in these patients has been linked to sexual dys-
functions, osteoporosis and even breast cancer.
Although it is often suggested that increased PRL levels
are responsible for sexual dysfunctions in schizophrenic
patients, one is struck by the fact that the literature on this
topic is limited [128, 428] and that the evidence is con-
tradictory and inconclusive [128, 129, 429, 430]. Some
studies have shown an association between sexual side
effects and PRL elevation, while others have failed to
support this [431]. From all evidence taken together, one
can conclude that it is highly unlikely that PRL elevation is
the sole cause of sexual dysfunctions, and that multiple
causes for sexual dysfunction in schizophrenic patients
should be considered [5]. Specific pharmacological pro-
files, especially with regard to the noradrenergic and
serotonergic receptors, the impact of the illness itself (e.g.,
the presence of negative or depressive symptoms), and the
impact of patients’ psychosocial settings need to be con-
sidered as well [129, 429]. Moreover, a recent study,
assessing sexual function in individuals at ultra-high risk of
psychosis, showed that sexual function is already impaired
prior to the onset of the first episode (and thus initiation of
treatment with antipsychotics), with half of these individ-
uals showing evidence of sexual dysfunction. These high
rates of dysfunction were not specific to particular domains
of sexual function [432].
Also regarding antipsychotic medication and osteopo-
rosis conflicting results exist. Some studies [433–437]
suggest antipsychotics contribute to a small increase in the
risk of fractures, while others do not [438, 439]. Of the
studies examining the relationship between antipsychotic-
induced HPRL and bone mineral density loss, about 60 %
found some effects of HPRL on bone mineral density
[440]. However, as in the case of sexual dysfunctions, the
etiology of osteoporosis is multifactorial [441] and the
relative contributions of antipsychotic-related HPRL and
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the influence of important unhealthy lifestyle behaviors in
this population (such as smoking and reduced physical
activity) remain unclear; more definitive, prospective,
long-term studies that directly assess relevant confounding
variables are needed [440]. The precise link between HPRL
and osteoporosis also remains to be elucidated [5]. There
are two potential mechanisms by which HPRL may result
in bone mineral density reductions: a direct one in the
absence of hypogonadism, and an indirect one mediated
(via the hypothalamic–pituitary–gonadal axis) through
suppression of gonadal hormone levels [9, 442].
There is accumulating epidemiological, clinical, and
biological evidence confirming a role of PRL in human
breast cancer risk [8, 443, 444]. However, although an
association has been demonstrated, a cause and effect
relationship is yet to be established [445]. In vitro and
in vivo studies strongly support that PRL is involved in
processes related to late-stage carcinogenic effects of
breast cancer, including increasing cell proliferation and
reducing apoptosis. Thus, it is possible that high circulating
PRL levels are important only after a preclinical lesion has
developed and promotes late-stage carcinogenesis [443].
The majority of the limited number of studies in which the
risk of breast cancer has been investigated in patients
treated with FGAs (e.g., [446–448]) or SGAs [449] did not
disclose an increased risk of breast cancer. Even exclusive
users of PRL-elevating SGAs, such as risperidone, were
found not to be at an increased risk of breast cancer [449].
However, based on the above mentioned cancer research
on the association between breast cancer risk and PRL, it
seems prudent to avoid PRL-elevating medications in
women with a history of breast cancer and possibly in those
with a strong family history of breast cancer [46, 55, 67,
427].
8 Conclusion
Hyperprolactinemia is often defined as a PRL concentra-
tion greater than the upper reference limit of the local
laboratory. However, a critical review of the literature
shows a substantial variation in reference intervals for
serum PRL. Differences in study design, the use of con-
comitant PRL-elevating medication, the short overall study
duration of most studies, the lack of PRL baseline values
and information on previous treatments and/or PRL mea-
surements in a substantial number of studies, make the
interpretation and comparison of data even more difficult.
As rates of HPRL will be dependent on many factors, such
as the timing of PRL measurement, these factors may be
relevant confounders for some data sets. Units of mea-
surement also cause some confusion: US data are often
presented in ng/ml whereas most UK and EU data are in
mIU/l; conversion rates are not standardized and vary
depending on the assay employed. Finally, clinical reports
do not always report the reference interval for serum PRL
while speaking about HPRL. Although many studies on
PRL are done by pharmaceutical companies, a recent large-
scale meta-analysis on antipsychotics (including an ana-
lysis on the PRL-inducing properties of these compounds)
showed efficacy outcomes did not change substantially
when pharmaceutical industry sponsorship was accounted
for in meta-regressions and sensitivity analyses [299].
Antipsychotics differ in their propensity to cause PRL
elevation. Although a discrimination of ‘‘PRL-sparing’’
versus ‘‘PRL-elevating’’ antipsychotic drugs may provide
the clinician with treatment choices in order to avoid or
mitigate HPRL, these terms can be misleading for clini-
cians, concluding that antipsychotic medications such as
aripiprazole, clozapine and quetiapine can never be asso-
ciated with significant HPRL. Actually, all antipsychotics
(FGAs, SGAs and newly approved antipsychotics) have the
propensity, especially during the first hours of treatment, to
elevate PRL levels above the upper limit of normal and to
induce HPRL. However, differences between antipsychotic
Table 5 Consequences of hyperprolactinemia
Irregular menstrual cycle
Amenorrhea: complete absence of menstruation
Menorrhagia: excessive menstrual bleeding
Oligomenorrhea: long and irregular intervals between two
successive menstrual periods
Anovulation (absence of ovulation)
Polymenorrhea: short and irregular intervals between two
menstrual periods
Abnormal semen production
Hypospermia (low sperm count)
Azoospermia (complete absence of sperm cells in the semen)
Fertility disorders/infertility
Galactorrhea (secretion of milk from the nipples in men and the
same phenomenon in non-lactating women) and gynecomastia
(excessive development of the male mammary glands)
Sexual dysfunction
Decreased libido, impaired arousal, impaired orgasm
Erectile dysfunction and ejaculation dysfunction
Impotence
Hypogonadism
Inadequate functioning of the sex glands (gonads), as a result of
which the levels of testosterone in the blood in men and of
estrogen in women are abnormally low
Hirsutism (male hair growth) and acne in women, due to relative
androgen excess compared with low estrogen levels
Obesity
Decreased bone mineral density, which may lead to increased risk
of osteoporosis
Breast cancer (?)
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drugs with respect to PRL elevation are large. Among the
FGAs, especially the high PRL risk of sulpiride is known.
Among the SGAs, amisulpride, risperidone and paliperi-
done are associated with the greatest elevation of PRL.
Olanzapine and ziprasidone do this with a moderate
severity. Although clozapine can raise (generally tran-
siently) PRL levels, these mostly remain within normal
range. During treatment with quetiapine, PRL levels are
mostly found to remain unchanged or to decrease over all
dosages, in most cases from levels at switch of treatment.
Aripiprazole shows the most benign PRL profile as, in
most studies, PRL levels were found to remain unchan-
ged or to decrease, even below those expected from
placebo, in adults as well as in children and adolescents.
Nevertheless, important consideration must always be
given to adolescents and children, who may be more
vulnerable than adults to PRL increases and at higher risk
of developing HPRL. Recent research also has shown that
HPRL can be pre-existing in a substantial proportion of
antipsychotic-naı¨ve patients with first-episode psychosis
or at-risk mental state. This pre-existing vulnerability
and/or a genetic predisposition must therefore be taken
into account when considering this important antipsy-
chotic side effect in these populations. Due to the overall
paucity of data on the newly approved antipsychotics,
there is still insufficient evidence to draw firm conclu-
sions concerning the PRL safety profile of these com-
pounds. Therefore, there is a clear need for further
controlled trials to evaluate how safe these newly
approved antipsychotics really are and which of these
agents are potentially less problematic regarding PRL
than most other ‘‘older’’ SGAs.
Prolactin elevations with antipsychotic medication are
mostly gender-related and dose-related. However, anti-
psychotics having a high potential for PRL elevation
(amisulpride and risperidone) can have a profound impact
on PRL levels even at relatively low doses, while PRL
levels with antipsychotics having a minimal effect on PRL
(aripiprazole) can remain unchanged over all dosages.
Although tolerance and decreases in PRL values after long-
term administration of PRL-elevating antipsychotics can
occur, these elevations, in most cases, remain above the
upper limit of normal.
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